Announcements Trials
Browse Landscape

Phase

Phase 2 1Phase 1 1

Status

Completed 2Recruiting 1No longer available 1

Sponsor Class

OTHER 1NIH 1

Study Type

Interventional 2

Sponsor

Cancer Type

CNS 2Sarcoma 1

Conditions

Melanoma 114Carcinoma, Non-Small-Cell Lung 34Neoplasms 26Neoplasm Metastasis 19Prostatic Neoplasms 18Uveal Melanoma 16Carcinoma, Renal Cell 16Lung Neoplasms 14Pancreatic Neoplasms 13Diabetes Mellitus, Insulin-Dependent, 12 12Small Cell Lung Carcinoma 11Colorectal Neoplasms 10Carcinoma, Hepatocellular 9Uterine Cervical Neoplasms 8Squamous Cell Carcinoma of Head and Neck 8Breast Neoplasms 8Sarcoma 7Carcinoma, Transitional Cell 7Brain Neoplasms 7Stomach Neoplasms 6Mesothelioma 6Kidney Neoplasms 6Head and Neck Neoplasms 6Advanced Cancer 6Urinary Bladder Neoplasms 5Recurrence 5Ovarian Neoplasms 5Lymphoma, Non-Hodgkin 5Lymphoma 5Leukemia, Myeloid, Acute 5

Interventions

Temozolomide 88Bevacizumab 49Radiotherapy 36Irinotecan 22Magnetic Resonance Spectroscopy 21Surgical Procedures, Operative 17Carboplatin 17Carmustine 15Radiation 13Nivolumab 11IL13-PE38 8Erlotinib Hydrochloride 8Thalidomide 7Radiotherapy, Intensity-Modulated 7Lomustine 7Imatinib Mesylate 7Everolimus 7Aminolevulinic Acid 7sargramostim 6Topotecan 6O(6)-benzylguanine 6Cyclophosphamide 6Chemotherapy, Adjuvant 6vandetanib 5temsirolimus 5fluorodopa F 18 5Vincristine 5Surveys and Questionnaires 5Radiosurgery 5Flucytosine 5

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Completed × Glioma × Ipilimumab × Clear all
NCT04817254 2026-04-17

Association of Peripheral Blood Immunologic Response to Therapeutic Response to Adjuvant Treatment With Immune Checkpoint Inhibition (ICI) in Patients With Newly Diagnosed Glioblastoma or Gliosarcoma

National Institutes of Health Clinical Center (CC)

Phase 2 Completed
47 enrolled
CNSSarcoma

Brain Neoplasms, Glioblastoma, Glioma, Gliosarcoma

NCT02829931 2023-01-19

Hypofractionated Stereotactic Irradiation With Nivolumab, Ipilimumab and Bevacizumab in Patients With Recurrent High Grade Gliomas

H. Lee Moffitt Cancer Center and Research Institute

Phase 1 Completed
33 enrolled
CNS

Glioma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡